Patents by Inventor James V. Snider
James V. Snider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11525828Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.Type: GrantFiled: June 14, 2019Date of Patent: December 13, 2022Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Patent number: 11340236Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: GrantFiled: September 6, 2019Date of Patent: May 24, 2022Assignees: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Patent number: 11340222Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a whole blood sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad holds the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The test strip also includes a plurality of second antibodies that bind to ST2, and a plurality of third antibodies that bind to the conjugate-ST2 complexes. The plurality of second antibodies are bound to a membrane in a test location, and the plurality of third antibodies are bound to the membrane in a control location. A plasma separation pad passes blood plasma from a whole blood sample to the conjugate pad while inhibiting other components.Type: GrantFiled: May 21, 2019Date of Patent: May 24, 2022Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Patent number: 11170896Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 12, 2018Date of Patent: November 9, 2021Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Publication number: 20210255200Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: ApplicationFiled: April 27, 2021Publication date: August 19, 2021Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20210164976Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: February 4, 2021Publication date: June 3, 2021Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 11016103Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: August 13, 2018Date of Patent: May 25, 2021Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Patent number: 10928393Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: October 25, 2018Date of Patent: February 23, 2021Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Publication number: 20200339695Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.Type: ApplicationFiled: July 13, 2020Publication date: October 29, 2020Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20200335220Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: July 7, 2020Publication date: October 22, 2020Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10745484Abstract: Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.Type: GrantFiled: August 28, 2015Date of Patent: August 18, 2020Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 10741290Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 10, 2019Date of Patent: August 11, 2020Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20200041507Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a whole blood sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad holds the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The test strip also includes a plurality of second antibodies that bind to ST2, and a plurality of third antibodies that bind to the conjugate-ST2 complexes. The plurality of second antibodies are bound to a membrane in a test location, and the plurality of third antibodies are bound to the membrane in a control location. A plasma separation pad passes blood plasma from a whole blood sample to the conjugate pad while inhibiting other components.Type: ApplicationFiled: May 21, 2019Publication date: February 6, 2020Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Publication number: 20200035357Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.Type: ApplicationFiled: June 14, 2019Publication date: January 30, 2020Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Publication number: 20190391162Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: ApplicationFiled: September 6, 2019Publication date: December 26, 2019Applicants: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Patent number: 10408845Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: GrantFiled: December 6, 2016Date of Patent: September 10, 2019Assignees: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Patent number: 10393756Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.Type: GrantFiled: November 1, 2017Date of Patent: August 27, 2019Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20190237197Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: April 10, 2019Publication date: August 1, 2019Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Patent number: 10324089Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a whole blood sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad holds the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The test strip also includes a plurality of second antibodies that bind to ST2, and a plurality of third antibodies that bind to the conjugate-ST2 complexes. The plurality of second antibodies are bound to a membrane in a test location, and the plurality of third antibodies are bound to the membrane in a control location. A plasma separation pad passes blood plasma from a whole blood sample to the conjugate pad while inhibiting other components.Type: GrantFiled: December 11, 2014Date of Patent: June 18, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Patent number: 10325682Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.Type: GrantFiled: September 11, 2018Date of Patent: June 18, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung